232 related articles for article (PubMed ID: 31654056)
1. BCL11A: a potential diagnostic biomarker and therapeutic target in human diseases.
Yin J; Xie X; Ye Y; Wang L; Che F
Biosci Rep; 2019 Nov; 39(11):. PubMed ID: 31654056
[TBL] [Abstract][Full Text] [Related]
2. Control of human hemoglobin switching by LIN28B-mediated regulation of BCL11A translation.
Basak A; Munschauer M; Lareau CA; Montbleau KE; Ulirsch JC; Hartigan CR; Schenone M; Lian J; Wang Y; Huang Y; Wu X; Gehrke L; Rice CM; An X; Christou HA; Mohandas N; Carr SA; Chen JJ; Orkin SH; Lander ES; Sankaran VG
Nat Genet; 2020 Feb; 52(2):138-145. PubMed ID: 31959994
[TBL] [Abstract][Full Text] [Related]
3. Human fetal hemoglobin expression is regulated by the developmental stage-specific repressor BCL11A.
Sankaran VG; Menne TF; Xu J; Akie TE; Lettre G; Van Handel B; Mikkola HK; Hirschhorn JN; Cantor AB; Orkin SH
Science; 2008 Dec; 322(5909):1839-42. PubMed ID: 19056937
[TBL] [Abstract][Full Text] [Related]
4. Binding patterns of BCL11A in the globin and GATA1 loci and characterization of the BCL11A fetal hemoglobin locus.
Jawaid K; Wahlberg K; Thein SL; Best S
Blood Cells Mol Dis; 2010 Aug; 45(2):140-6. PubMed ID: 20542454
[TBL] [Abstract][Full Text] [Related]
5. The rs61742690 (S783N) single nucleotide polymorphism is a suitable target for disrupting BCL11A-mediated foetal-to-adult globin switching.
Abdulazeez S; Sultana S; Almandil NB; Almohazey D; Bency BJ; Borgio JF
PLoS One; 2019; 14(2):e0212492. PubMed ID: 30768627
[TBL] [Abstract][Full Text] [Related]
6. BCL11A deletions result in fetal hemoglobin persistence and neurodevelopmental alterations.
Basak A; Hancarova M; Ulirsch JC; Balci TB; Trkova M; Pelisek M; Vlckova M; Muzikova K; Cermak J; Trka J; Dyment DA; Orkin SH; Daly MJ; Sedlacek Z; Sankaran VG
J Clin Invest; 2015 Jun; 125(6):2363-8. PubMed ID: 25938782
[TBL] [Abstract][Full Text] [Related]
7. Identification of deleterious SNPs and their effects on BCL11A, the master regulator of fetal hemoglobin expression.
Das SS; Chakravorty N
Genomics; 2020 Jan; 112(1):397-403. PubMed ID: 30853596
[TBL] [Abstract][Full Text] [Related]
8. Featured Article: Modulation of fetal hemoglobin in hereditary persistence of fetal hemoglobin deletion type-2, compared to Sicilian δβ-thalassemia, by BCL11A and SOX6-targeting microRNAs.
Fornari TA; Lanaro C; Albuquerque DM; Ferreira R; Costa FF
Exp Biol Med (Maywood); 2017 Feb; 242(3):267-274. PubMed ID: 27591578
[TBL] [Abstract][Full Text] [Related]
9. BCL11A promotes myeloid leukemogenesis by repressing PU.1 target genes.
Sunami Y; Yokoyama T; Yoshino S; Takahara T; Yamazaki Y; Harada H; Nakamura T
Blood Adv; 2022 Mar; 6(6):1827-1843. PubMed ID: 34714913
[TBL] [Abstract][Full Text] [Related]
10. Hemoglobin switching's surprise: the versatile transcription factor BCL11A is a master repressor of fetal hemoglobin.
Bauer DE; Orkin SH
Curr Opin Genet Dev; 2015 Aug; 33():62-70. PubMed ID: 26375765
[TBL] [Abstract][Full Text] [Related]
11. Evolution of nanobodies specific for BCL11A.
Yin M; Izadi M; Tenglin K; Viennet T; Zhai L; Zheng G; Arthanari H; Dassama LMK; Orkin SH
Proc Natl Acad Sci U S A; 2023 Jan; 120(3):e2218959120. PubMed ID: 36626555
[TBL] [Abstract][Full Text] [Related]
12. Regulation of the MIR155 host gene in physiological and pathological processes.
Elton TS; Selemon H; Elton SM; Parinandi NL
Gene; 2013 Dec; 532(1):1-12. PubMed ID: 23246696
[TBL] [Abstract][Full Text] [Related]
13. Bcl11a Deficiency Leads to Hematopoietic Stem Cell Defects with an Aging-like Phenotype.
Luc S; Huang J; McEldoon JL; Somuncular E; Li D; Rhodes C; Mamoor S; Hou S; Xu J; Orkin SH
Cell Rep; 2016 Sep; 16(12):3181-3194. PubMed ID: 27653684
[TBL] [Abstract][Full Text] [Related]
14. BCL11A mRNA Targeting by miR-210: A Possible Network Regulating γ-Globin Gene Expression.
Gasparello J; Fabbri E; Bianchi N; Breveglieri G; Zuccato C; Borgatti M; Gambari R; Finotti A
Int J Mol Sci; 2017 Nov; 18(12):. PubMed ID: 29186860
[TBL] [Abstract][Full Text] [Related]
15. Regulation of the fetal hemoglobin silencing factor BCL11A.
Basak A; Sankaran VG
Ann N Y Acad Sci; 2016 Mar; 1368(1):25-30. PubMed ID: 26963603
[TBL] [Abstract][Full Text] [Related]
16. BCL11A Is Oncogenic and Predicts Poor Outcomes in Natural Killer/T-Cell Lymphoma.
Shi H; Li C; Feng W; Yue J; Song J; Peng A; Wang H
Front Pharmacol; 2020; 11():820. PubMed ID: 32625084
[TBL] [Abstract][Full Text] [Related]
17. Brain malformations in a patient with deletion 2p16.1: A refinement of the phenotype to BCL11A.
Balci TB; Sawyer SL; Davila J; Humphreys P; Dyment DA
Eur J Med Genet; 2015; 58(6-7):351-4. PubMed ID: 25979662
[TBL] [Abstract][Full Text] [Related]
18. BCL11A-dependent recruitment of SIRT1 to a promoter template in mammalian cells results in histone deacetylation and transcriptional repression.
Senawong T; Peterson VJ; Leid M
Arch Biochem Biophys; 2005 Feb; 434(2):316-25. PubMed ID: 15639232
[TBL] [Abstract][Full Text] [Related]
19. Phenotypic-screening generates active novel fetal globin-inducers that downregulate Bcl11a in a monkey model.
Makino T; Haruyama M; Katayama K; Terashima H; Tsunemi T; Miyazaki K; Terakawa M; Yamashiro K; Yoshioka R; Maeda H
Biochem Pharmacol; 2020 Jan; 171():113717. PubMed ID: 31751536
[TBL] [Abstract][Full Text] [Related]
20. Hemoglobin genetics: recent contributions of GWAS and gene editing.
Smith EC; Orkin SH
Hum Mol Genet; 2016 Oct; 25(R2):R99-R105. PubMed ID: 27340226
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
